Bio-Rad Laboratories, Inc.
Every calculator, already run for BIO
Open the full toolkit →You have the numbers on BIO. Get the argument.
A written report on which of these readings actually decide the outcome for Bio-Rad Laboratories, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
5 analysts covering BIOAnalyst Price Target Disagreement for Bio-Rad Laboratories, Inc.
Wall Street's bull case implies +4% from the current price; the bear case implies -26%. Analysts are relatively aligned on BIO's range.
Ownership & short interest
Insider Trading Activity for BIO
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment se…
BIO — frequently asked
Is BIO a buy right now?
Wall Street's consensus rating on Bio-Rad Laboratories, Inc. is Hold across 5 analysts, with a mean price target of $329.00 (-13% vs. the current $376.41). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is BIO overvalued?
BIO trades at 45.8x trailing earnings, against a DCF fair value of $269 per share. The current price implies 10% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is BIO's next earnings date?
Bio-Rad Laboratories, Inc. is next scheduled to report earnings around Oct 29, 2026. A full BIO research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Bio-Rad Laboratories, Inc.?
Analysts covering Bio-Rad Laboratories, Inc. (BIO) range from a bear-case target of $280.00 to a bull-case high of $390.00, with a mean consensus target of $329.00 across 5 analysts. The spread of $110.00 (29% of the current price) indicates moderate disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Bio-Rad Laboratories, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Bio-Rad Laboratories, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full BIO research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Bio-Rad Laboratories, Inc., in minutes. 3 free reports included with every account — no credit card required.